Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Psychiatric Disorders Impeding Weight Loss in Obese Breast Cancer Survivors.

Hryniuk W, Jenkins I, Djuric Z.

J Clin Oncol. 2016 Apr 1;34(10):1152-3. doi: 10.1200/JCO.2015.65.5639. Epub 2016 Jan 25. No abstract available.

PMID:
26811517
2.

Patient perceptions of a comprehensive cancer navigation service.

Hryniuk W, Simpson R, McGowan A, Carter P.

Curr Oncol. 2014 Apr;21(2):69-76. doi: 10.3747/co.21.1930.

3.

Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline.

Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH; American Society of Clinical Oncology.

J Clin Oncol. 2012 May 1;30(13):1553-61. doi: 10.1200/JCO.2011.39.9436. Epub 2012 Apr 2. Review.

PMID:
22473167
4.

Disentangling the effects of race on breast cancer treatment.

Banerjee M, George J, Yee C, Hryniuk W, Schwartz K.

Cancer. 2007 Nov 15;110(10):2169-77.

5.

Quality of life as a predictor of weight loss in obese, early-stage breast cancer survivors.

Darga LL, Magnan M, Mood D, Hryniuk WM, DiLaura NM, Djuric Z.

Oncol Nurs Forum. 2007 Jan;34(1):86-92.

PMID:
17562636
6.

Random control clinical trial on the effects of aerobic exercise training on erythrocyte levels during radiation treatment for breast cancer.

Drouin JS, Young TJ, Beeler J, Byrne K, Birk TJ, Hryniuk WM, Hryniuk LE.

Cancer. 2006 Nov 15;107(10):2490-5.

7.

Dosage parameters in chemotherapy of breast cancer.

Hryniuk W.

Breast Dis. 2001;14:21-30.

PMID:
15687633
8.

Tree-based model for breast cancer prognostication.

Banerjee M, George J, Song EY, Roy A, Hryniuk W.

J Clin Oncol. 2004 Jul 1;22(13):2567-75.

PMID:
15226324
9.

Improvement of metabolism among obese breast cancer survivors in differing weight loss regimens.

Jen KL, Djuric Z, DiLaura NM, Buison A, Redd JN, Maranci V, Hryniuk WM.

Obes Res. 2004 Feb;12(2):306-12.

10.

Dose density by any other name.

Hryniuk W, Ragaz J, Peters W.

J Clin Oncol. 2004 Feb 15;22(4):750-1; author reply 751-3. No abstract available.

PMID:
14966105
11.

Relationship of psychiatric diagnosis and weight loss maintenance in obese breast cancer survivors.

Jenkins I, Djuric Z, Darga L, DiLaura NM, Magnan M, Hryniuk WM.

Obes Res. 2003 Nov;11(11):1369-75.

12.

Combining weight-loss counseling with the weight watchers plan for obese breast cancer survivors.

Djuric Z, DiLaura NM, Jenkins I, Darga L, Jen CK, Mood D, Bradley E, Hryniuk WM.

Obes Res. 2002 Jul;10(7):657-65.

13.

Expedition inspiration consensus 2001.

Benz CC, Hilakivi-Clarke L, Conzen S, Dorn RV, Fleming GF, Grant K, Greene G, Hellman S, Henderson C, Hoover R, Hryniuk W, Jeffrey S, Lippman M, Lung J, Mitchell M, Pike M.

Breast Cancer Res Treat. 2001 Dec;70(3):213-9. No abstract available.

14.

Oral sequelae of chemotherapy: an important teaching opportunity for oncology health care providers and their patients.

Sadler GR, Oberle-Edwards L, Farooqi A, Hryniuk WM.

Support Care Cancer. 2000 May;8(3):209-14.

PMID:
10789962
15.

Importance of chemotherapy scheduling: pieces of the puzzle.

Hryniuk W.

Cancer Invest. 1999;17(7):545-6. No abstract available.

PMID:
10518199
16.

Re: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer.

Hryniuk W.

J Natl Cancer Inst. 1999 Aug 18;91(16):1425. No abstract available.

PMID:
10451457
17.

The relationship between high-dose treatment and combination chemotherapy: the concept of summation dose intensity.

Frei E 3rd, Elias A, Wheeler C, Richardson P, Hryniuk W.

Clin Cancer Res. 1998 Sep;4(9):2027-37. Review.

18.
19.

Time for a change.

Hryniuk W.

Cancer J Sci Am. 1997 Jul-Aug;3(4):209-10. No abstract available.

PMID:
9263625
20.

Feasibility of a randomized trial of a high-vegetable diet to prevent breast cancer recurrence.

Pierce JP, Faerber S, Wright FA, Newman V, Flatt SW, Kealey S, Rock CL, Hryniuk W, Greenberg ER.

Nutr Cancer. 1997;28(3):282-8.

PMID:
9343838
21.

"Decadose" effects of cisplatin on squamous cell carcinoma of the upper aerodigestive tract. II. Clinical studies.

Robbins KT, Storniolo AM, Hryniuk WM, Howell SB.

Laryngoscope. 1996 Jan;106(1 Pt 1):37-42.

PMID:
8544625
22.

Will increases in dose intensity improve outcome: pro.

Hryniuk W.

Am J Med. 1995 Dec 29;99(6A):69S-70S. No abstract available.

PMID:
8585543
23.

Interleukin 2-induced focal fatty infiltrate of the liver that mimics metastases.

Lilenbaum RC, Lilenbaum AM, Hryniuk WM.

J Natl Cancer Inst. 1995 Apr 19;87(8):609-10. No abstract available.

PMID:
7752261
24.

Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis.

Levin L, Simon R, Hryniuk W.

J Natl Cancer Inst. 1993 Nov 3;85(21):1732-42.

PMID:
8411257
25.

CHOP versus m-BACOD in non-Hodgkin's lymphoma.

Hryniuk W.

N Engl J Med. 1993 Feb 25;328(8):581. No abstract available.

PMID:
7678920
26.

Dose intensity and lymphoma.

Meyer R, Goodyear M, Hryniuk W.

J Clin Oncol. 1991 Aug;9(8):1511. No abstract available.

PMID:
2072151
27.

What were the received dose intensities in the three arms?

Hryniuk WM.

J Clin Oncol. 1991 Jul;9(7):1321-2. No abstract available.

PMID:
2045873
28.

The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma.

Meyer RM, Hryniuk WM, Goodyear MD.

J Clin Oncol. 1991 Feb;9(2):339-47.

PMID:
1824863
29.

The calculation of received dose intensity.

Hryniuk WM, Goodyear M.

J Clin Oncol. 1990 Dec;8(12):1935-7. No abstract available.

PMID:
2230885
30.

A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer.

Levine MN, Gent M, Hryniuk WM, Bramwell V, Abu-Zahra H, DePauw S, Arnold A, Findlay B, Levin L, Skillings J, et al.

J Clin Oncol. 1990 Jul;8(7):1217-25.

PMID:
2193119
31.

Integrating the concept of dose intensity into a strategy for systemic therapy of malignant disease.

Hryniuk WM.

Prog Clin Biol Res. 1990;354B:93-101. No abstract available.

PMID:
2236177
32.

Recruitment for an efficacy study in chemoprevention--the Concerned Smoker Study.

Arnold A, Johnstone B, Stoskopf B, Skingley P, Browman G, Levine M, Hryniuk W.

Prev Med. 1989 Sep;18(5):700-10.

PMID:
2694164
33.

Dose intensity: a critique of a critical review.

Hryniuk WM.

J Clin Oncol. 1989 May;7(5):681-4. No abstract available.

PMID:
2651583
34.

Correlation of dose intensity and prognosis in adjuvant chemotherapy: an extended controversy.

Hryniuk WM.

Recent Results Cancer Res. 1989;115:17-24. No abstract available.

PMID:
2696029
35.

Quality of life in stage II breast cancer: an instrument for clinical trials.

Levine MN, Guyatt GH, Gent M, De Pauw S, Goodyear MD, Hryniuk WM, Arnold A, Findlay B, Skillings JR, Bramwell VH, et al.

J Clin Oncol. 1988 Dec;6(12):1798-810.

PMID:
3058874
36.

More is better.

Hryniuk WM.

J Clin Oncol. 1988 Sep;6(9):1365-7. No abstract available.

PMID:
3047331
37.

The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer.

Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W, De Pauw S.

N Engl J Med. 1988 Feb 18;318(7):404-7.

PMID:
3340118
38.

The importance of dose intensity in the outcome of chemotherapy.

Hryniuk WM.

Important Adv Oncol. 1988:121-41. Review. No abstract available.

PMID:
3042601
39.

Applications of dose intensity to problems in chemotherapy of breast and colorectal cancer.

Hryniuk WM, Figueredo A, Goodyear M.

Semin Oncol. 1987 Dec;14(4 Suppl 4):3-11.

PMID:
3317849
40.

The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer.

Levin L, Hryniuk W.

Semin Oncol. 1987 Dec;14(4 Suppl 4):12-9.

PMID:
3120317
41.

Generation of dose intensity-response data suggested for drug studies.

Hryniuk WM.

Cancer Treat Rep. 1987 Nov;71(11):1125-6. No abstract available.

PMID:
3677118
42.

Dose intensity analysis of chemotherapy regimens in ovarian carcinoma.

Levin L, Hryniuk WM.

J Clin Oncol. 1987 May;5(5):756-67.

PMID:
3572465
43.

A ten-year update of CHOP-BLEO in the treatment of diffuse large-cell lymphoma.

Hryniuk WM.

J Clin Oncol. 1987 Apr;5(4):682. No abstract available.

PMID:
2435859
44.

Average relative dose intensity and the impact on design of clinical trials.

Hryniuk WM.

Semin Oncol. 1987 Mar;14(1):65-74. No abstract available.

PMID:
3823917
45.

Drug dosage intensity--a panel discussion.

McGuire WL, Goldie J, Hryniuk W, Tormey DC.

Breast Cancer Res Treat. 1987;9(2):87-100.

PMID:
3620720
46.

Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer.

Hryniuk W, Levine MN.

J Clin Oncol. 1986 Aug;4(8):1162-70.

PMID:
3525765
47.

Is more better?

Hryniuk WM.

J Clin Oncol. 1986 May;4(5):621-2. No abstract available.

PMID:
3517239
48.

Analysis of dose intensity for chemotherapy in early (stage II) and advanced breast cancer.

Hryniuk WM, Levine MN, Levin L.

NCI Monogr. 1986;(1):87-94.

PMID:
3534595
49.

Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer.

Figueredo AT, Hryniuk WM, Strautmanis I, Frank G, Rendell S.

J Clin Oncol. 1985 Jan;3(1):54-64.

PMID:
2981292
50.

The importance of dose intensity in chemotherapy of metastatic breast cancer.

Hryniuk W, Bush H.

J Clin Oncol. 1984 Nov;2(11):1281-8. Review. No abstract available.

PMID:
6387060

Supplemental Content

Loading ...
Support Center